Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/16/2018 02/20/2018 02/21/2018 02/22/2018 02/23/2018 Date
68.96(c) 67.35(c) 66.53(c) 65.94(c) 67.95(c) Last
10 547 419 8 703 677 7 046 249 6 528 408 5 081 211 Volume
-0.03% -2.33% -1.22% -0.89% +3.05% Change
More quotes
Financials ($)
Sales 2018 21 689 M
EBIT 2018 5 672 M
Net income 2018 5 211 M
Finance 2018 852 M
Yield 2018 2,46%
Sales 2019 23 418 M
EBIT 2019 6 590 M
Net income 2019 6 075 M
Finance 2019 3 568 M
Yield 2019 2,53%
P/E ratio 2018 21,90
P/E ratio 2019 18,58
EV / Sales2018 4,98x
EV / Sales2019 4,50x
Capitalization 109 B
More Financials
Company
Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.It includes chemically-synthesized drugs or small molecules and products produced from biological... 
Sector
Pharmaceuticals
Calendar
04/26Earnings Release
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
02/23BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb Co. Describe Advan..
AQ
02/23BRISTOL MYERS SQUIBB : Research Conducted at Bristol-Myers Squibb Has Updated Ou..
AQ
02/23Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Br..
BU
02/23BRISTOL MYERS SQUIBB : Demonstrates Their Commitment to Site Relationships by Jo..
AQ
02/22THE KLEIN LAW FIRM : Reminds Investors of an Investigation Concerning Possible V..
BU
02/22Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 fr..
BU
02/21BRISTOL MYERS SQUIBB : Why dozens of lawsuits against diabetes drug are coming t..
AQ
02/21THE KLEIN LAW FIRM : Notifies Investors of an Investigation Concerning Possible ..
BU
02/19BRISTOL MYERS SQUIBB : and Nektar Therapeutics Announce Global Development & Com..
AQ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
More news
Sector news : Pharmaceuticals - NEC
02/23PUMA BIOTECHNOLOGY : EU panel recommends against nod for Puma Biotech's breast c..
RE
02/23SANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/23SHIRE : FDA to Conduct Priority Review of Shire Genetic-Disorder Drug
DJ
02/23NOVARTIS : Greek Parliament Approves Bribery and Price Fix Inquiry on Novartis -..
DJ
02/22NOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB COMPA 
BRISTOL-MYERS SQUIBB CO - 2016
Attractive price levels
BUY
More Strategies
Latest Tweets
02/23Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Br.. 
02/23$AZN $BMY $CRVS $MRK $NVS $OMED $PFE $RHHBY $RCUS  
02/23At least two interesting bits here: 1. $PFE sizing up $BMY for acquisition (I..
5
02/23$BMY said the cuts as part of its broader R&D reorg, telling Fierce the a..
3
02/23Pomerantz Law Firm Announces the Filing of a Class Action against Bristol-Mye.. 
More tweets
Qtime:180
News from SeekingAlpha
02/23Arcus Biosciences Files To Raise $100 Million In IPO 
02/21Bristol-Myers Squibb Sows Confusion 
02/20BRISTOL-MYERS SQUIBB : Next Stop, Record Levels 
02/20Nektar And Bristol-Myers Squibb's Deal Could Be An Opportunity For NewLink 
02/20THE NO BS PLAN : Week 1 Report 
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 65,1 $
Spread / Average Target -2,1%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY8.57%108 890
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618